JP2017532316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532316A5 JP2017532316A5 JP2017515228A JP2017515228A JP2017532316A5 JP 2017532316 A5 JP2017532316 A5 JP 2017532316A5 JP 2017515228 A JP2017515228 A JP 2017515228A JP 2017515228 A JP2017515228 A JP 2017515228A JP 2017532316 A5 JP2017532316 A5 JP 2017532316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- substituted
- oxytocin receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 102000004279 Oxytocin receptors Human genes 0.000 claims 6
- 108090000876 Oxytocin receptors Proteins 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229940044601 receptor agonist Drugs 0.000 claims 4
- 239000000018 receptor agonist Substances 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 2
- 229940122381 Oxytocin receptor agonist Drugs 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 108700021293 carbetocin Proteins 0.000 claims 2
- 229960001118 carbetocin Drugs 0.000 claims 2
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 229960000310 isoleucine Drugs 0.000 claims 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 0 C[C@@](C(C)=O)NC(CC**)=O Chemical compound C[C@@](C(C)=O)NC(CC**)=O 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019181930A JP6921154B2 (ja) | 2014-09-19 | 2019-10-02 | プラダー・ウィリー症候群を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052957P | 2014-09-19 | 2014-09-19 | |
| US62/052,957 | 2014-09-19 | ||
| PCT/US2015/049911 WO2016044131A1 (en) | 2014-09-19 | 2015-09-14 | Method of treating prader-willi syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181930A Division JP6921154B2 (ja) | 2014-09-19 | 2019-10-02 | プラダー・ウィリー症候群を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532316A JP2017532316A (ja) | 2017-11-02 |
| JP2017532316A5 true JP2017532316A5 (enExample) | 2018-09-20 |
| JP6599447B2 JP6599447B2 (ja) | 2019-10-30 |
Family
ID=54238564
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515228A Active JP6599447B2 (ja) | 2014-09-19 | 2015-09-14 | プラダー・ウィリー症候群を治療する方法 |
| JP2019181930A Active JP6921154B2 (ja) | 2014-09-19 | 2019-10-02 | プラダー・ウィリー症候群を治療する方法 |
| JP2021041334A Pending JP2021098745A (ja) | 2014-09-19 | 2021-03-15 | プラダー・ウィリー症候群を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019181930A Active JP6921154B2 (ja) | 2014-09-19 | 2019-10-02 | プラダー・ウィリー症候群を治療する方法 |
| JP2021041334A Pending JP2021098745A (ja) | 2014-09-19 | 2021-03-15 | プラダー・ウィリー症候群を治療する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10441627B2 (enExample) |
| EP (2) | EP3666258B1 (enExample) |
| JP (3) | JP6599447B2 (enExample) |
| CN (2) | CN112773765A (enExample) |
| CA (1) | CA2957224A1 (enExample) |
| DK (1) | DK3666258T3 (enExample) |
| ES (2) | ES2775425T3 (enExample) |
| FI (1) | FI3666258T3 (enExample) |
| HR (1) | HRP20240166T1 (enExample) |
| HU (1) | HUE065829T2 (enExample) |
| LT (1) | LT3666258T (enExample) |
| PL (1) | PL3666258T3 (enExample) |
| PT (1) | PT3666258T (enExample) |
| RS (1) | RS65144B1 (enExample) |
| SI (1) | SI3666258T1 (enExample) |
| WO (1) | WO2016044131A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2957224A1 (en) * | 2014-09-19 | 2016-03-24 | Ferring B.V. | Method of treating prader-willi syndrome |
| US10981955B2 (en) | 2017-08-11 | 2021-04-20 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
| US10736894B2 (en) | 2018-02-15 | 2020-08-11 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with PDE10A inhibitors |
| AU2019345313A1 (en) | 2018-09-20 | 2021-03-18 | Levo Therapeutics, Inc. | Carbetocin drug product and process for preparing same |
| CN112839632A (zh) * | 2018-09-20 | 2021-05-25 | 莱沃疗法公司 | 稳定的鼻内卡贝缩宫素制剂 |
| US20240050494A1 (en) * | 2020-12-18 | 2024-02-15 | The General Hospital Corporation | Probiotics compositions and method of using the same to enhance growth and social function in children |
| PL4313106T3 (pl) | 2021-03-26 | 2025-09-01 | Ot4B | Leczenie dysfagii |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7544662B2 (en) | 1993-06-17 | 2009-06-09 | Carle Development Foundation | Polypeptides useful for appetite suppression |
| US6894026B1 (en) | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| WO2008150305A1 (en) | 2007-06-07 | 2008-12-11 | Nastech Pharmaceutical Company Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| CA2699169A1 (en) | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Therapeutic uses of intermedin 47 and 53 peptides |
| CA2704724A1 (en) | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | 5use of a peptide as a therapeutic agent |
| WO2009033820A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| EP2197463A2 (en) | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections |
| HRP20140716T1 (hr) | 2008-03-31 | 2014-08-29 | Ferring B.V. | Analozi oksitocina |
| CA2731020A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| US8853158B2 (en) | 2010-05-25 | 2014-10-07 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods for the treatment of a feeding disorder with onset during neonate development using an agonist of the oxytocin receptor |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| WO2012149472A2 (en) | 2011-04-27 | 2012-11-01 | Ignite Institute For Individualized Health | Methods, compositions, and kits for treating and preventing neurological conditions |
| EA026687B1 (ru) | 2012-12-21 | 2017-05-31 | Ф. Хоффманн-Ля Рош Аг | Пептиды в качестве агонистов окситоцина |
| KR20150108384A (ko) * | 2013-01-17 | 2015-09-25 | 에프. 호프만-라 로슈 아게 | 중추신경계 질병의 치료를 위한 옥시토신 수용체 작용제 |
| EA030091B1 (ru) | 2014-06-03 | 2018-06-29 | Ф. Хоффманн-Ля Рош Аг | Пептиды, выполняющие роль агонистов окситоцина |
| CR20160562A (es) | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
| SI3177635T1 (sl) | 2014-08-07 | 2019-01-31 | F. Hoffmann-La Roche Ag | Postopki za pripravo analogov oksitocina |
| CA2957224A1 (en) * | 2014-09-19 | 2016-03-24 | Ferring B.V. | Method of treating prader-willi syndrome |
-
2015
- 2015-09-14 CA CA2957224A patent/CA2957224A1/en active Pending
- 2015-09-14 CN CN202110278199.4A patent/CN112773765A/zh active Pending
- 2015-09-14 FI FIEP19216650.2T patent/FI3666258T3/fi active
- 2015-09-14 CN CN201580049147.2A patent/CN106714819A/zh active Pending
- 2015-09-14 JP JP2017515228A patent/JP6599447B2/ja active Active
- 2015-09-14 DK DK19216650.2T patent/DK3666258T3/da active
- 2015-09-14 RS RS20240134A patent/RS65144B1/sr unknown
- 2015-09-14 LT LTEP19216650.2T patent/LT3666258T/lt unknown
- 2015-09-14 ES ES15772107T patent/ES2775425T3/es active Active
- 2015-09-14 PT PT192166502T patent/PT3666258T/pt unknown
- 2015-09-14 EP EP19216650.2A patent/EP3666258B1/en active Active
- 2015-09-14 HR HRP20240166TT patent/HRP20240166T1/hr unknown
- 2015-09-14 PL PL19216650.2T patent/PL3666258T3/pl unknown
- 2015-09-14 WO PCT/US2015/049911 patent/WO2016044131A1/en not_active Ceased
- 2015-09-14 EP EP15772107.7A patent/EP3193907B1/en active Active
- 2015-09-14 US US15/510,781 patent/US10441627B2/en active Active
- 2015-09-14 SI SI201531990T patent/SI3666258T1/sl unknown
- 2015-09-14 HU HUE19216650A patent/HUE065829T2/hu unknown
- 2015-09-14 ES ES19216650T patent/ES2970059T3/es active Active
-
2019
- 2019-10-02 JP JP2019181930A patent/JP6921154B2/ja active Active
- 2019-10-03 US US16/592,632 patent/US20200129584A1/en not_active Abandoned
-
2021
- 2021-03-15 JP JP2021041334A patent/JP2021098745A/ja active Pending
-
2022
- 2022-11-18 US US18/057,065 patent/US20240082344A1/en active Pending